Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance

For eligible patients with newly-diagnosed multiple myeloma (MM), induction therapy with bortezomib, lenalidomide and dexamethasone (VRD) followed by autologous transplant (autoHCT) and lenalidomide (Len) maintenance is generally the most commonly used treatment approach. However, there are scarce d...

Full description

Bibliographic Details

Published in:	Transplantation and cellular therapy Vol. 31; no. 2; p. S421
Main Authors:	Pasvolsky, Oren, Milton, Denai R., Tanner, Mark R., Bashir, Qaiser, Srour, Samer A., Saini, Neeraj Y., Lin, Paul, Siddiqui, Umer R., Khan, Hina N., Haider, Asad A., Ramdial, Jeremy L., Nieto, Yago, Tang, Guilin, Lakhani, Kiran, Aljawai, Yosra M., Kebriaei, Partow, Lee, Hans C., Patel, Krina K., Thomas, Sheeba K., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H.
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01.02.2025
ISSN:	2666-6367, 2666-6367
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!